Metabolic Syndrome and Associated Diseases: From the Bench to the Clinic

Metabolic Syndrome and Associated Diseases: From the Bench to the Clinic, a Society of Toxicology Contemporary Concepts in Toxicology (CCT) workshop was held on March 11, 2017. The meeting was convened to raise awareness of metabolic syndrome and its associated diseases and serve as a melting pot wi...

Full description

Saved in:

Bibliographic Details
Published in:	Toxicological sciences Vol. 162; no. 1; p. 36
Main Authors:	Mendrick, Donna L, Diehl, Anna Mae, Topor, Lisa S, Dietert, Rodney R, Will, Yvonne, La Merrill, Michele A, Bouret, Sebastien, Varma, Vijayalaskshmi, Hastings, Kenneth L, Schug, Thaddeus T, Emeigh Hart, Susan G, Burleson, Florence G
Format:	Journal Article
Language:	English
Published:	United States 01.03.2018
Subjects:	Animals Biomedical Research - methods Biomedical Research - trends Clinical Medicine - methods Clinical Medicine - trends Drug-Related Side Effects and Adverse Reactions - etiology Drug-Related Side Effects and Adverse Reactions - genetics Drug-Related Side Effects and Adverse Reactions - immunology Environmental Pollutants - toxicity Humans Life Style Metabolic Syndrome - chemically induced Metabolic Syndrome - etiology Metabolic Syndrome - genetics Metabolic Syndrome - immunology
ISSN:	1096-0929, 1096-0929
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Metabolic Syndrome and Associated Diseases: From the Bench to the Clinic, a Society of Toxicology Contemporary Concepts in Toxicology (CCT) workshop was held on March 11, 2017. The meeting was convened to raise awareness of metabolic syndrome and its associated diseases and serve as a melting pot with scientists of multiple disciplines (eg, toxicologists, clinicians, regulators) so as to spur research and understanding of this condition. The criteria for metabolic syndrome include obesity, dyslipidemia (low high-density lipoprotein and/or elevated triglycerides), elevated blood pressure, and alterations in glucose metabolism. It can lead to a greater potential of type 2 diabetes, lipid disorders, cardiovascular disease, hepatic steatosis, and other circulatory disorders. Although there are no approved drugs specifically for this syndrome, many drugs target diseases associated with this syndrome thus potentially increasing the likelihood of drug-drug interactions. There is currently significant research focusing on understanding the key pathways that control metabolism, which would be likely targets of risk factors (eg, exposure to xenobiotics, genetics) and lifestyle factors (eg, microbiome, nutrition, and exercise) that contribute to metabolic syndrome. Understanding these pathways could also lead to the development of pharmaceutical interventions. As individuals with metabolic syndrome have signs similar to that of toxic responses (eg, oxidative stress and inflammation) and organ dysfunction, these alterations should be taken into account in drug development. With the increasing frequency of metabolic syndrome in the general population, the idea of a "normal" individual may need to be redefined. This paper reports on the substance and outcomes of this workshop.
AbstractList	Metabolic Syndrome and Associated Diseases: From the Bench to the Clinic, a Society of Toxicology Contemporary Concepts in Toxicology (CCT) workshop was held on March 11, 2017. The meeting was convened to raise awareness of metabolic syndrome and its associated diseases and serve as a melting pot with scientists of multiple disciplines (eg, toxicologists, clinicians, regulators) so as to spur research and understanding of this condition. The criteria for metabolic syndrome include obesity, dyslipidemia (low high-density lipoprotein and/or elevated triglycerides), elevated blood pressure, and alterations in glucose metabolism. It can lead to a greater potential of type 2 diabetes, lipid disorders, cardiovascular disease, hepatic steatosis, and other circulatory disorders. Although there are no approved drugs specifically for this syndrome, many drugs target diseases associated with this syndrome thus potentially increasing the likelihood of drug-drug interactions. There is currently significant research focusing on understanding the key pathways that control metabolism, which would be likely targets of risk factors (eg, exposure to xenobiotics, genetics) and lifestyle factors (eg, microbiome, nutrition, and exercise) that contribute to metabolic syndrome. Understanding these pathways could also lead to the development of pharmaceutical interventions. As individuals with metabolic syndrome have signs similar to that of toxic responses (eg, oxidative stress and inflammation) and organ dysfunction, these alterations should be taken into account in drug development. With the increasing frequency of metabolic syndrome in the general population, the idea of a "normal" individual may need to be redefined. This paper reports on the substance and outcomes of this workshop. Metabolic Syndrome and Associated Diseases: From the Bench to the Clinic, a Society of Toxicology Contemporary Concepts in Toxicology (CCT) workshop was held on March 11, 2017. The meeting was convened to raise awareness of metabolic syndrome and its associated diseases and serve as a melting pot with scientists of multiple disciplines (eg, toxicologists, clinicians, regulators) so as to spur research and understanding of this condition. The criteria for metabolic syndrome include obesity, dyslipidemia (low high-density lipoprotein and/or elevated triglycerides), elevated blood pressure, and alterations in glucose metabolism. It can lead to a greater potential of type 2 diabetes, lipid disorders, cardiovascular disease, hepatic steatosis, and other circulatory disorders. Although there are no approved drugs specifically for this syndrome, many drugs target diseases associated with this syndrome thus potentially increasing the likelihood of drug-drug interactions. There is currently significant research focusing on understanding the key pathways that control metabolism, which would be likely targets of risk factors (eg, exposure to xenobiotics, genetics) and lifestyle factors (eg, microbiome, nutrition, and exercise) that contribute to metabolic syndrome. Understanding these pathways could also lead to the development of pharmaceutical interventions. As individuals with metabolic syndrome have signs similar to that of toxic responses (eg, oxidative stress and inflammation) and organ dysfunction, these alterations should be taken into account in drug development. With the increasing frequency of metabolic syndrome in the general population, the idea of a "normal" individual may need to be redefined. This paper reports on the substance and outcomes of this workshop.Metabolic Syndrome and Associated Diseases: From the Bench to the Clinic, a Society of Toxicology Contemporary Concepts in Toxicology (CCT) workshop was held on March 11, 2017. The meeting was convened to raise awareness of metabolic syndrome and its associated diseases and serve as a melting pot with scientists of multiple disciplines (eg, toxicologists, clinicians, regulators) so as to spur research and understanding of this condition. The criteria for metabolic syndrome include obesity, dyslipidemia (low high-density lipoprotein and/or elevated triglycerides), elevated blood pressure, and alterations in glucose metabolism. It can lead to a greater potential of type 2 diabetes, lipid disorders, cardiovascular disease, hepatic steatosis, and other circulatory disorders. Although there are no approved drugs specifically for this syndrome, many drugs target diseases associated with this syndrome thus potentially increasing the likelihood of drug-drug interactions. There is currently significant research focusing on understanding the key pathways that control metabolism, which would be likely targets of risk factors (eg, exposure to xenobiotics, genetics) and lifestyle factors (eg, microbiome, nutrition, and exercise) that contribute to metabolic syndrome. Understanding these pathways could also lead to the development of pharmaceutical interventions. As individuals with metabolic syndrome have signs similar to that of toxic responses (eg, oxidative stress and inflammation) and organ dysfunction, these alterations should be taken into account in drug development. With the increasing frequency of metabolic syndrome in the general population, the idea of a "normal" individual may need to be redefined. This paper reports on the substance and outcomes of this workshop.
Author	Dietert, Rodney R Mendrick, Donna L Diehl, Anna Mae La Merrill, Michele A Emeigh Hart, Susan G Varma, Vijayalaskshmi Topor, Lisa S Burleson, Florence G Schug, Thaddeus T Will, Yvonne Hastings, Kenneth L Bouret, Sebastien
Author_xml	– sequence: 1 givenname: Donna L surname: Mendrick fullname: Mendrick, Donna L organization: Regulatory Activities, National Center for Toxicological Research, Food and Drug Administration, Silver Spring, Maryland 20993 – sequence: 2 givenname: Anna Mae surname: Diehl fullname: Diehl, Anna Mae organization: Division of Gastroenterology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina 27710 – sequence: 3 givenname: Lisa S surname: Topor fullname: Topor, Lisa S organization: The Warren Alpert Medical School of Brown University; Pediatric Endocrinology Rhode Island Hospital Providence, Rhode Island 02903 – sequence: 4 givenname: Rodney R surname: Dietert fullname: Dietert, Rodney R organization: Department of Microbiology and Immunology, Cornell University College of Veterinary Medicine, Ithaca, New York 14853 – sequence: 5 givenname: Yvonne surname: Will fullname: Will, Yvonne organization: Drug Safety Research and Development, Pfizer, Groton, Connecticut 06340 – sequence: 6 givenname: Michele A surname: La Merrill fullname: La Merrill, Michele A organization: Department of Environmental Toxicology, University of California at Davis, Davis, California 95616 – sequence: 7 givenname: Sebastien surname: Bouret fullname: Bouret, Sebastien organization: Kerk School of Medicine, University of Southern California, Los Angeles, California 90027 and Jean-Pierre Aubert Research Center, Jean-Pierre Aubert Research Center, Lille, France – sequence: 8 givenname: Vijayalaskshmi surname: Varma fullname: Varma, Vijayalaskshmi organization: Division of Systems Biology, National Center for Toxicological Research, Food and Drug Administration, Jefferson, Arkansas 72079 – sequence: 9 givenname: Kenneth L surname: Hastings fullname: Hastings, Kenneth L organization: Hastings Toxicology Consulting LLC, Mount Airy, Maryland 21771 – sequence: 10 givenname: Thaddeus T surname: Schug fullname: Schug, Thaddeus T organization: Division of Extramural Research, National Institute of Environmental Health Sciences, Durham, North Carolina 27709 – sequence: 11 givenname: Susan G surname: Emeigh Hart fullname: Emeigh Hart, Susan G organization: Experimental Pathology, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut 06877 – sequence: 12 givenname: Florence G surname: Burleson fullname: Burleson, Florence G organization: Burleson Research Technologies Inc, Morrisville, North Carolina 27560
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/29106690$$D View this record in MEDLINE/PubMed
BookMark	eNpNT0lPAjEYbQxGFj16NT16GWmnpVBvOIqYYDyo50mXr6E60-K0JPDvJYqJp7fmJW-IeiEGQOiSkhtKJBvnuEvGjz_drmTsBA0OpiiILGXvH--jYUofhFAqiDxD_VJSIoQkA7R8hqx0bLzBr_tgu9gCVsHieUrReJXB4nufQCVIt3hxiHFeA76DYNY4xx9RNT54c45OnWoSXBxxhN4XD2_Vsli9PD5V81Vh-EzkgnLqpFQTqbnUyhotphwMd1BOZ5JqBVKp0hFJuBZgDOUTbZ1g1hFLnWOiHKHr391NF7-2kHLd-mSgaVSAuE01lYISxqYTcqheHatb3YKtN51vVbev_96X3_3VXtA
CitedBy_id	crossref_primary_10_1038_s41598_023_48402_z crossref_primary_10_3390_ijms242216177 crossref_primary_10_1097_APO_0000000000000515 crossref_primary_10_1097_JP9_0000000000000157 crossref_primary_10_2196_43737 crossref_primary_10_3390_jcm13226908 crossref_primary_10_1002_jbt_22840 crossref_primary_10_3389_ftox_2021_663372 crossref_primary_10_1038_s41588_024_01933_1 crossref_primary_10_3390_biom14040478 crossref_primary_10_1007_s40200_025_01692_8 crossref_primary_10_3389_fpubh_2024_1415916 crossref_primary_10_1016_j_ctim_2020_102505 crossref_primary_10_1016_j_envint_2024_108929 crossref_primary_10_3389_ti_2024_11075 crossref_primary_10_1007_s12291_021_00992_z crossref_primary_10_54022_shsv6n1_053 crossref_primary_10_4103_ijpvm_ijpvm_216_24 crossref_primary_10_1016_j_phymed_2024_155922 crossref_primary_10_1016_j_tjnut_2024_06_017 crossref_primary_10_2188_jea_JE20210185 crossref_primary_10_3389_fspor_2023_1197925 crossref_primary_10_1007_s13167_021_00243_4 crossref_primary_10_1134_S1990519X23010108 crossref_primary_10_3389_fendo_2020_583006 crossref_primary_10_1080_1028415X_2023_2223390 crossref_primary_10_1161_CIR_0000000000000950 crossref_primary_10_1161_CIR_0000000000001123 crossref_primary_10_1016_j_bbadis_2020_165688 crossref_primary_10_1155_2021_2972610 crossref_primary_10_1016_j_ijcrp_2024_200279 crossref_primary_10_3389_fendo_2021_651303 crossref_primary_10_1186_s12872_024_03779_1 crossref_primary_10_31482_mmsl_2022_039 crossref_primary_10_1097_MD_0000000000025303 crossref_primary_10_14814_phy2_14808 crossref_primary_10_1002_ptr_7327 crossref_primary_10_1002_mnfr_202000249 crossref_primary_10_1016_j_arcmed_2024_103043 crossref_primary_10_3390_medicina59081438 crossref_primary_10_3390_ijerph19042209 crossref_primary_10_1186_s12902_020_00563_y crossref_primary_10_17721_1728_2748_2020_80_50_56 crossref_primary_10_3389_fendo_2024_1365658 crossref_primary_10_1093_toxsci_kfy023 crossref_primary_10_1108_NFS_01_2022_0013 crossref_primary_10_3390_app11115066 crossref_primary_10_1016_j_ctim_2024_103092 crossref_primary_10_1002_JPER_22_0282 crossref_primary_10_3390_obesities5020027 crossref_primary_10_3390_medicina58070839 crossref_primary_10_3390_nu15112571 crossref_primary_10_3390_pr9111876 crossref_primary_10_3390_nu16223958 crossref_primary_10_1186_s12263_024_00757_2 crossref_primary_10_3390_medicina59101711 crossref_primary_10_1016_j_jhealeco_2025_103046 crossref_primary_10_3390_biomedicines9091140 crossref_primary_10_1186_s12885_023_11026_7 crossref_primary_10_3389_fpubh_2025_1604593 crossref_primary_10_1007_s00424_021_02638_8 crossref_primary_10_1136_bmjdrc_2020_001181 crossref_primary_10_1016_j_clnu_2024_04_034 crossref_primary_10_3390_antiox12122091 crossref_primary_10_3390_nu12102983 crossref_primary_10_1002_rco2_81 crossref_primary_10_1016_j_phrs_2022_106627 crossref_primary_10_1590_1518_8345_5758_3529 crossref_primary_10_4103_ijd_ijd_155_21 crossref_primary_10_1371_journal_pone_0224259 crossref_primary_10_1016_j_numecd_2020_11_020 crossref_primary_10_3390_nu16101441 crossref_primary_10_1002_art_42381 crossref_primary_10_1002_fft2_327 crossref_primary_10_1515_intox_2017_0013 crossref_primary_10_3390_biomedicines12010242 crossref_primary_10_3390_nu16060871 crossref_primary_10_1016_j_scitotenv_2024_171123 crossref_primary_10_2174_1381612826666201019102640 crossref_primary_10_1016_j_chemosphere_2020_128362 crossref_primary_10_1249_MSS_0000000000002580 crossref_primary_10_31146_1682_8658_ecg_183_11_74_79 crossref_primary_10_3390_jcm8122033 crossref_primary_10_3389_fnagi_2020_00185 crossref_primary_10_3390_jpm11100943 crossref_primary_10_2196_65440 crossref_primary_10_3390_ijms23084387 crossref_primary_10_1016_j_celrep_2025_115690 crossref_primary_10_1016_j_tifs_2025_105227 crossref_primary_10_1186_s12905_023_02876_1 crossref_primary_10_1111_1753_0407_13342 crossref_primary_10_3390_s22145200 crossref_primary_10_3390_molecules26092438 crossref_primary_10_1093_cdn_nzaa130 crossref_primary_10_3389_fendo_2019_00788 crossref_primary_10_1097_MS9_0000000000001630 crossref_primary_10_1161_CIR_0000000000000757 crossref_primary_10_1161_CIR_0000000000001209 crossref_primary_10_1016_j_neuint_2020_104694 crossref_primary_10_1080_15592294_2019_1695340 crossref_primary_10_1016_j_hrtlng_2025_07_019 crossref_primary_10_1002_lim2_25 crossref_primary_10_1161_CIR_0000000000001052 crossref_primary_10_2174_2212798412666220318162322 crossref_primary_10_1186_s41043_024_00580_w crossref_primary_10_1038_s42003_022_04237_4 crossref_primary_10_3390_ijerph19063181 crossref_primary_10_1080_00325481_2022_2140511 crossref_primary_10_1007_s11695_019_04360_y crossref_primary_10_1016_j_micres_2024_127667 crossref_primary_10_21303_2504_5695_2020_001194 crossref_primary_10_1016_j_ijmedinf_2024_105480 crossref_primary_10_1016_j_nutres_2021_11_004 crossref_primary_10_1186_s12944_020_01411_7 crossref_primary_10_1007_s40200_024_01513_4 crossref_primary_10_1038_s41398_025_03289_4 crossref_primary_10_1186_s12889_025_21571_4 crossref_primary_10_1186_s13098_019_0439_5 crossref_primary_10_1016_j_jtemb_2020_126651 crossref_primary_10_3390_jcm13216607 crossref_primary_10_1080_19390211_2022_2107138 crossref_primary_10_1590_1518_8345_5758_3579 crossref_primary_10_1038_s41598_020_64130_0 crossref_primary_10_1590_1518_8345_5758_3578 crossref_primary_10_3390_ijms25094909 crossref_primary_10_1016_j_arabjc_2023_105501 crossref_primary_10_1038_s41598_024_69707_7 crossref_primary_10_1111_nbu_12537 crossref_primary_10_1155_2020_5206204 crossref_primary_10_3389_fphys_2024_1464744 crossref_primary_10_1186_s12902_024_01763_6 crossref_primary_10_1371_journal_pone_0262526 crossref_primary_10_1016_j_bbagrm_2018_12_006 crossref_primary_10_1186_s13098_024_01440_7 crossref_primary_10_1016_j_ctcp_2022_101625 crossref_primary_10_1177_01939459211018824 crossref_primary_10_7759_cureus_59118 crossref_primary_10_1161_CIR_0000000000001303 crossref_primary_10_1016_j_chemosphere_2024_141493 crossref_primary_10_1016_j_jtcme_2021_08_011 crossref_primary_10_1007_s12020_022_02979_z crossref_primary_10_1016_j_jafr_2025_101819 crossref_primary_10_37155_2972_449X_0102_7 crossref_primary_10_3390_molecules26020283 crossref_primary_10_1186_s13098_018_0311_z crossref_primary_10_1093_milmed_usae016 crossref_primary_10_1194_jlr_RA120000781 crossref_primary_10_3389_fcvm_2020_613271 crossref_primary_10_3389_fimmu_2020_00818 crossref_primary_10_3390_nu14081535 crossref_primary_10_2147_DMSO_S450783
ContentType	Journal Article
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1093/toxsci/kfx233
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine Public Health Pharmacy, Therapeutics, & Pharmacology
EISSN	1096-0929
ExternalDocumentID	29106690
Genre	Review Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural
GrantInformation_xml	– fundername: NIDDK NIH HHS grantid: R01 DK102780 – fundername: NIEHS NIH HHS grantid: R01 ES024946 – fundername: NIDDK NIH HHS grantid: R01 DK084142 – fundername: NIEHS NIH HHS grantid: R00 ES019919
GroupedDBID	--- -E4 .2P .I3 .ZR 0R~ 123 18M 1~5 29Q 2WC 4.4 48X 4G. 53G 5RE 5VS 5WA 5WD 7-5 70D A8Z AABZA AACZT AAHBH AAIMJ AAJKP AAJQQ AAMDB AAMVS AAOGV AAPNW AAPQZ AAPXW AARHZ AAUAY AAUQX AAVAP AAVLN AAYWO ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABMNT ABNHQ ABNKS ABPQP ABPTD ABQLI ABVGC ABWST ABXVV ABXZS ABZBJ ACGFO ACGFS ACUFI ACUTJ ACUTO ADBBV ADEYI ADEZT ADGKP ADGZP ADHKW ADHZD ADIPN ADNBA ADOCK ADQBN ADRTK ADVEK ADYVW ADZTZ ADZXQ AEGPL AEGXH AEJOX AEKSI AELWJ AEMDU AENEX AENZO AEPUE AETBJ AEWNT AFFZL AFGWE AFIYH AFOFC AGINJ AGKEF AGORE AGQXC AGSYK AHMMS AHXPO AIJHB AJBYB AJEEA AJNCP AKHUL AKRWK AKWXX ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APWMN ARIXL ATGXG AXUDD AYOIW BAWUL BAYMD BCRHZ BEYMZ BHONS BQDIO BSWAC BTRTY BVRKM CDBKE CGR CS3 CUY CVF CZ4 DAKXR DIK DILTD DU5 D~K E3Z EBD EBS ECM EDH EE~ EIF EJD EMOBN F5P F9B FDB FHSFR FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HH5 HW0 HZ~ I-F IOX JXSIZ KAQDR KBUDW KOP KQ8 KSI KSN M-Z N9A NGC NLBLG NOMLY NOYVH NPM NQ- NU- O-L O9- OAWHX OBOKY OCZFY ODMLO OJQWA OJZSN OPAEJ OWPYF P2P PAFKI PEELM Q1. Q5Y R44 RD5 ROL ROX RUSNO RW1 RXO SV3 TJX TLC TR2 W8F WOQ X7H YAYTL YKOAZ YXANX ZKX ~02 ~91 7X8 ESTFP
ID	FETCH-LOGICAL-c486t-141f99a59b49badcb674ec4fe27891bae9aa2f0904b6ecc145bdf63df0d1ff362
IEDL.DBID	7X8
ISICitedReferencesCount	158
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000427020900006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1096-0929
IngestDate	Sat Sep 27 20:03:11 EDT 2025 Mon Jul 21 06:05:23 EDT 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	1
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c486t-141f99a59b49badcb674ec4fe27891bae9aa2f0904b6ecc145bdf63df0d1ff362
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23
OpenAccessLink	https://academic.oup.com/toxsci/article-pdf/162/1/36/24141147/kfx233.pdf
PMID	29106690
PQID	1961033750
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_1961033750 pubmed_primary_29106690
PublicationCentury	2000
PublicationDate	2018-03-01
PublicationDateYYYYMMDD	2018-03-01
PublicationDate_xml	– month: 03 year: 2018 text: 2018-03-01 day: 01
PublicationDecade	2010
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Toxicological sciences
PublicationTitleAlternate	Toxicol Sci
PublicationYear	2018
SSID	ssj0011609
Score	2.6170099
SecondaryResourceType	review_article
Snippet	Metabolic Syndrome and Associated Diseases: From the Bench to the Clinic, a Society of Toxicology Contemporary Concepts in Toxicology (CCT) workshop was held...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	36
SubjectTerms	Animals Biomedical Research - methods Biomedical Research - trends Clinical Medicine - methods Clinical Medicine - trends Drug-Related Side Effects and Adverse Reactions - etiology Drug-Related Side Effects and Adverse Reactions - genetics Drug-Related Side Effects and Adverse Reactions - immunology Environmental Pollutants - toxicity Humans Life Style Metabolic Syndrome - chemically induced Metabolic Syndrome - etiology Metabolic Syndrome - genetics Metabolic Syndrome - immunology
Title	Metabolic Syndrome and Associated Diseases: From the Bench to the Clinic
URI	https://www.ncbi.nlm.nih.gov/pubmed/29106690 https://www.proquest.com/docview/1961033750
Volume	162
WOSCitedRecordID	wos000427020900006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bS8MwFD6oExHEy7zNGxHEJ8uSNctWX8Tb2IMbAy_sbSRNgiK001bZ_r0nTceeBMGXQlsKJedLznfuAGeuuFFqpgJKpQg4UzRQKOuAC2mkbZlYFM6cl4dWv98eDqNB6XDLyrTK2ZlYHNQ6jZ2PvI5IYTQMUcFdjT8CNzXKRVfLERqLUAmRyriUrtZwHkVgokjxYNQl2iIPKHtsohFfz9MJqpj6u5003Mzc39hloWU6G__9v01YL_klufaA2IIFk1RhpVdG0KtwPvC9qqcX5GleepVdkHMymHexnlZhzTv0iK9T2oZuz-QIGPfosexyQGSiyUy-RpM7H-zJLkkHXxOkluQGN8ErydPixvcg3YHnzv3TbTcoxzAEMW-LPGCc2SiSzUjxSEkdK9HiJubWuCJapqSJpGxYGlGuBAKC8abSVoTaUs2sRQW5C0tJmph9ICFVxlDtYocxZ3FDSoSKs1AN5SGaTjU4nS3uCGHuYhcyMelXNpovbw32vIRGY9-PY9RAyiPQyj_4w9eHsIqUp-2zyI6gYnGTm2NYjr_zt-zzpMAPXvuD3g_yotBJ
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Metabolic+Syndrome+and+Associated+Diseases%3A+From+the+Bench+to+the+Clinic&rft.jtitle=Toxicological+sciences&rft.au=Mendrick%2C+Donna+L&rft.au=Diehl%2C+Anna+Mae&rft.au=Topor%2C+Lisa+S&rft.au=Dietert%2C+Rodney+R&rft.date=2018-03-01&rft.issn=1096-0929&rft.eissn=1096-0929&rft.volume=162&rft.issue=1&rft.spage=36&rft_id=info:doi/10.1093%2Ftoxsci%2Fkfx233&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1096-0929&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1096-0929&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1096-0929&client=summon